|
1
|
Chiarle R, Voena C, Ambrogio C, Piva R and
Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of
cancer. Nat Rev Cancer. 8:11–23. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dirks WG, Fähnrich S, Lis Y, Becker E,
MacLeod RA and Drexler HG: Expression and functional analysis of
the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int
J Cancer. 100:49–56. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niu HT, Zhou QM, Wang F, Shao Q, Guan YX,
Wen XZ, Chen LZ, Feng QS, Li W, Zeng YX and Zhang XS:
Identification of anaplastic lymphoma kinase break points and
oncogenic mutation profiles in acral/mucosal melanomas. Pigment
Cell Melanoma Res. 26:646–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wiesner T, Lee W, Obenauf AC, Ran L,
Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH, et al:
Alternative transcription initiation leads to expression of a novel
ALK isoform in cancer. Nature. 526:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Busam KJ, Vilain RE, Lum T, Busam JA,
Hollmann TJ, Saw RP, Coit DC, Scolyer RA and Wiesner T: Primary and
metastatic cutaneous melanomas express ALK through alternative
transcriptional initiation. Am J Surg Pathol. 40:786–795. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sanlorenzo M, Ribero S, Osella-Abate S,
Zugna D, Marenco F, Macripò G, Fierro MT, Bernengo MG and Quaglino
P: Prognostic differences across sexes in melanoma patients: What
has changed from the past? Melanoma Res. 24:568–576. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ribero S, Osella-Abate S, Sanlorenzo M,
Balagna E, Senetta R, Fierro MT, Macripò G, Macrì L, Sapino A and
Quaglino P: Sentinel lymph node biopsy in thick-melanoma patients
(N=350): What is its prognostic role? Ann Surg Oncol. 22:1967–1973.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Osella-Abate S, Ribero S, Sanlorenzo M,
Maule MM, Richiardi L, Merletti F, Tomasini C, Marra E, Macripò G,
Fierro MT and Quaglino P: Risk factors related to late metastases
in 1,372 melanoma patients disease free more than 10 years. Int J
Cancer. 136:2453–2457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mariani S, Di Bello C, Bonello L, Tondat
F, Pacchioni D, Molinaro L, Barreca A, Macrì L, Chiusa L, di Celle
PF, et al: Flexible lab-tailored cut-offs for suitability of
formalin-fixed tumor samples for diagnostic mutational analyses.
PLoS One. 10:e01218152015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Agnelli L, Mereu E, Pellegrino E, Limongi
T, Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J, Piccaluga PP,
et al: Identification of a 3-gene model as a powerful diagnostic
tool for the recognition of ALK-negative anaplastic large-cell
lymphoma. Blood. 120:1274–1284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scarfò I, Pellegrino E, Mereu E, Kwee I,
Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti
R, et al: Identification of a new subclass of ALK-negative ALCL
expressing aberrant levels of ERBB4 transcripts. Blood.
127:221–232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
George RE, Sanda T, Hanna M, Fröhling S,
Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al:
Activating mutations in ALK provide a therapeutic target in
neuroblastoma. Nature. 455:975–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iwahara T, Fujimoto J, Wen D, Cupples R,
Bucay N, Arakawa T, Mori S, Ratzkin B and Yamamoto T: Molecular
characterization of ALK, a receptor tyrosine kinase expressed
specifically in the nervous system. Oncogene. 14:439–449. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
https://www.ncbi.nlm.nih.gov/nuccore/NM_004304?report=GenBankHomo
sapiens ALK receptor tyrosine kinase (ALK), transcript variant 1.
mRNA.
|
|
15
|
https://www.ncbi.nlm.nih.gov/nuccore/NM_007439.2?report=GenBankMus
musculus anaplastic lymphoma kinase (Alk). mRNA.
|
|
16
|
Forsea AM, Del Marmol V, de Vries E,
Bailey EE and Geller AC: Melanoma incidence and mortality in
Europe: New estimates, persistent disparities. Br J Dermatol.
167:1124–1130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Svedman FC, Pillas D, Taylor A, Kaur M,
Linder R and Hansson J: Stage-specific survival and recurrence in
patients with cutaneous malignant melanoma in Europe-a systematic
review of the literature. Clin Epidemiol. 8:109–122. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson DB, Lovly CM, Flavin M, Panageas
KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, et
al: Impact of NRAS mutations for patients with advanced melanoma
treated with immune therapies. Cancer Immunol Res. 3:288–295. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jakob JA, Bassett RL Jr, Ng CS, Curry JL,
Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim
KB, et al: NRAS mutation status is an independent prognostic factor
in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arozarena I and Wellbrock C: Targeting
invasive properties of melanoma cells. FEBS J. 284:2148–2162. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thul PJ, Åkesson L, Wiking M, Mahdessian
D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM,
et al: A subcellular map of the human proteome. Science. 356(pii):
eaal33212017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morris SW, Kirstein MN, Valentine MB,
Dittmer K, Shapiro DN, Look AT and Saltman DL: Fusion of a kinase
gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's
lymphoma. Science. 267:316–317. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Platz A, Egyhazi S, Ringborg U and Hansson
J: Human cutaneous melanoma; a review of NRAS and BRAF mutation
frequencies in relation to histogenetic subclass and body site. Mol
Oncol. 1:395–405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hiniker SM, Reddy SA, Maecker HT,
Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, Saha S, Shura L
and Knox SJ: A prospective clinical trial combining radiation
therapy with systemic immunotherapy in metastatic melanoma. Int J
Radiat Oncol Biol Phys. 96:578–588. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Churilla TM and Weiss SE: Emerging trends
in the management of brain metastases from non-small cell lung
cancer. Curr Oncol Rep. 20:542018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Couts KL, Bemis J, Turner JA, Bagby SM,
Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, et
al: ALK inhibitor response in melanomas expressing EML4-ALK fusions
and alternate ALK isoforms. Mol Cancer Ther. 17:222–231. 2018.
View Article : Google Scholar : PubMed/NCBI
|
